

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	Application Number	10/559,806
				Confirmation Number	Unknown
				Filing Date	December 8, 2005
				First Named Inventor	Jin-Soo KIM
				Art Unit	Unknown 1636
				Examiner Name	Unknown J. Dunston
				Attorney Docket Number	Q91925

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁴
		H. HARADA et al., "Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells", <i>Cancer Research</i> , Vol. 62, April 1, 2002, pp. 2013-2018	
		H. WU et al., "Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain", <i>Neuroscience Research</i> , Vol. 47, 2003, pp. 131-135	
		T. TAKENOBU et al., "Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells", <i>Molecular Cancer Therapeutics</i> , Vol. 1, October 2002, pp. 1043-1049	
		A. HO et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential <i>in Vitro</i> and <i>in Vivo</i> ", <i>Cancer Research</i> , Vol. 61, January 15, 2001, pp. 474-477	
		A.D. FRANKEL et al., "Tat Protein from Human Immunodeficiency Virus Forms a Metal-Linked Dimer", <i>Science</i> , Vol. 240, April 1, 1988, pp. 70-73	
		D.R. GIUS et al., "Transduced p16 ^{INK4a} Peptides Inhibit Hypophosphorylation of the Retinoblastoma Protein and Cell Cycle Progression Prior to Activation of Cdk2 Complexes in Late G ₁ ", <i>Cancer Research</i> , Vol. 59, June 1, 1999, pp. 2577-2580	
		E.L. Snyder and S.F. Dowdy, "Cell Penetrating Peptides in Drug Delivery", <i>Pharmaceutical Research</i> , Vol. 21, No. 3, March 2004, pp. 389-393	
		A. VOCERO-AKBANI et al., "Transduction of Full-Length Tat Fusion Proteins Directly into Mammalian Cells: Analysis of T Cell Receptor Activation-Induced Cell Death", <i>Methods in Enzymology</i> , Vol. 322, 2000, pp. 508-521	

Examiner Signature	/Jennifer Dunston/ (04/24/2008)	Date Considered	
--------------------	---------------------------------	-----------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/ (04/24/2008)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to indicate here if English language Translation is attached.